產品屬性：
產品名稱 | POMHEX |
規格 | 5 mg、10 mg、25 mg、50 mg |
貨號 | EY-01Y10792 |
Cas No.: 2004714-34-3
別名: N/A
化學名: N/A
分子式: C17H30NO9P
分子量: 423.4
溶解度: DMSO : 100 mg/mL (236.18 mM; Need ultrasonic)
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
POMHEX, a racemic mixture and a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX, is a potent, ENO2-specific inhibitor of enolase. POMHEX exhibits low-nanomolar potency against ENO1-deleted cells in vitro and is capable of eradicating ENO1-deleted xenografted tumours in vivo. POMHEX is a potent glycolysis inhibitor[1].POMHEX (78 nM, 8h) minimally impacts ENO1-WT glioma cells but profoundly affected ENO1-deleted cells[1].POMHEX (0-720 nM) selectively induces energy stress, inhibits proliferation and triggers apoptosis in ENO1-deleted glioma cells[1].POMHEX (i.v., ip) injections are consistently tolerated without haemolytic anaemia at doses of up to 10 mg per kg (body weight) per day. POMHEX (i.v., 35 mg/kg) results in lethargy that prompted veterinarians to perform euthanasia[1].POMHEX is rapidly hydrolysed to HemiPOMHEX in mouse plasma ex vivo, with a half-lifeof approximately 30 s, the half-life in human blood ex vivo was about 9min[1].[1]. Yu-Hsi Lin, et al. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 Nov 23.
特別提醒公司產品僅供科研使用
